Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

602
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
602
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

534
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
534
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

942
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
942
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

897
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
897
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

793
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
793

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary Description of Clinical Characteristics and Outcomes in Patients with Hereditary ATTR Amyloidosis: Results from the Multicountry OverTTuRe Study.

Cardiology and therapy·2026
Same author

Variant classification for mucopolysaccharidosis type I; ACMG/AMP specification for IDUA from the ClinGen lysosomal diseases variant curation expert panel.

Molecular genetics and metabolism·2026
Same author

Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy.

European journal of heart failure·2026
Same author

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.

Gynecologic oncology·2026
Same author

Factors Related To Improving the Quality of Cervical Cancer Screening for Women Living with HIV in La Romana, Dominican Republic: A Qualitative Descriptive Study.

AIDS and behavior·2026
Same author

Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03.

Neuro-oncology practice·2026
Same journal

Application of ephrin-B2 loaded glycol chitosan-silk fibroin hydrogel in the treatment of diabetic refractory wounds.

Scientific reports·2026
Same journal

International expert Delphi consensus on thromboprophylaxis in metabolic and bariatric surgery.

Scientific reports·2026
Same journal

Assessing the cross-region knowledge transfer capability of selected deep learning building vectorization methods in the context of available training datasets.

Scientific reports·2026
Same journal

Feasibility and preliminary effects of outdoor versus indoor cognitive-motor therapy in women with Alzheimer's disease: A randomized single-blind pilot study.

Scientific reports·2026
Same journal

Hallmarks of social action in the vocal turn-taking of wild common marmosets (Callithrix jacchus).

Scientific reports·2026
Same journal

Role and mechanism of AOPPs-induced NOX4-mediated ferroptosis in intervertebral disc degeneration.

Scientific reports·2026
See all related articles

Related Experiment Video

Updated: Aug 5, 2025

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K

LNA blockers for improved amplification selectivity.

Jaime Prout1, Michael Tian1, Alicia Palladino1

  • 1Department of Genomics and Computational Biology, Homology Medicines, Inc., Bedford, MA, 01730, USA.

Scientific Reports
|March 25, 2023
PubMed
Summary
This summary is machine-generated.

Locked nucleic acids (LNAs) effectively block unwanted DNA amplification, even with slight sequence differences. Optimal blocker design involves specific LNA placement and length for high specificity and efficiency.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K

Related Experiment Videos

Last Updated: Aug 5, 2025

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K

Area of Science:

  • Molecular Biology
  • Biotechnology
  • Genetics

Background:

  • Locked nucleic acids (LNAs) exhibit enhanced DNA binding affinity compared to standard DNA oligonucleotides.
  • LNAs can selectively inhibit the amplification of specific DNA sequences, particularly when target DNA is present at low concentrations alongside similar, undesired sequences.

Purpose of the Study:

  • To optimize the design of LNA-containing oligonucleotides as blockers for DNA amplification.
  • To investigate the impact of LNA base length, number, and positioning on blocker effectiveness and specificity.

Main Methods:

  • Utilized short recombinant adeno-associated virus (rAAV) and synthetic DNA sequences as model systems.
  • Systematically varied oligonucleotide length, LNA base incorporation (number and position), and target sequence degeneracy to assess blocking efficiency.
  • Evaluated the effect of mismatches, blocker strand, and proximity to priming sites on blocking activity.
  • Designed and tested LNA blockers against wild-type DNA and the single-base A1AT PiZ allele.

Main Results:

  • Oligonucleotides of 18-24 bases with LNAs at alternating positions demonstrated the highest blocking effectiveness.
  • Mismatches at the ends of LNAs had minimal impact on blocking, and longer blockers tolerated single and double mismatches, especially near LNA ends.
  • Shorter LNAs exhibited greater selectivity, with more than one mismatch preventing effective blocking.
  • Neither the binding strand nor the distance to priming sites significantly affected blocker efficiency.
  • Optimal specificity was achieved when the mismatch was positioned away from the 5' end of the LNA.
  • Pairs of overlapping blockers on opposite strands with a central mismatch maximized activity and specificity.

Conclusions:

  • LNA oligonucleotide design, including length, LNA content, and mismatch positioning, is critical for effective and specific DNA amplification blocking.
  • The findings provide a framework for designing highly specific LNA blockers for applications such as allele-specific amplification and genotyping.
  • Optimized LNA blockers offer a powerful tool for discriminating between closely related DNA sequences.